A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-24 and is reviewed periodically as new material appears.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Plasma renin activity (PRA), also known as the renin (active) assay or random plasma renin, is a measure of the activity of the plasma enzyme renin, which plays a major role in the body's regulation of blood pressure, thirst, and urine output. Measure of direct renin concentration (DRC) is technically more demanding, and hence PRA is used instead. DRC assays are still in evolution, and generally a conversion factor of PRA (ng/mL/h) to DRC (mU/L) is 8.2. A recently developed and already commonly used automated DRC assay uses the conversion factor of 12. PRA is sometimes measured, specially in case of certain diseases which present with hypertension or hypotension. PRA is also raised in certain tumors. A PRA measurement may be compared to a plasma aldosterone concentration as an aldosterone-to-renin ratio (ARR).
==== Service to the Allies during World War II ==== Jung was in contact with Allen Dulles of the Office of Strategic Services (predecessor of the Central Intelligence Agency) and provided valuable intelligence on the psychological condition of Hitler. Dulles referred to Jung as "Agent 488" and offered the following description of his service: "Nobody will probably ever know how much Professor Jung contributed to the Allied Cause during the war, by seeing people who were connected somehow with the other side". Jung's service to the Allied cause through the OSS remained classified after the war.
Dover grew further after the Norman invasion of 1066 as a member of the Confederation of Cinque Ports. After the martyrdom of Archbishop Thomas Becket at Canterbury Cathedral in 1170, Dover flourished as the only designated port of entry for foreign pilgrims and as a point of departure for the third and subsequent crusades. Following Edward III's success at the Battle of Sluys in 1340, a large defensive wall was built around the town. Although few concerted attempts to manage the shingle deposits blocking the harbour entrance were made during the late Middle Ages, a short pier and two defensive towers were constructed at the port in years immediately prior to Henry VIII's departure to the royal summit known as the Field of the Cloth of Gold in 1520.
=== Structure of graphite and its intercalation compounds === In 1859, Benjamin Brodie noted the highly lamellar structure of thermally reduced graphite oxide. Researchers used X-ray crystallography in an attempt to determine the structure of graphite. The lack of large single crystal graphite specimens contributed to the independent development of X-ray powder diffraction by Peter Debye and Paul Scherrer in 1915, and Albert Hull in 1916. However, neither of their proposed structures was correct. In 1918, Volkmar Kohlschütter and P. Haenni described the properties of graphite oxide paper. The structure of graphite was successfully determined from single-crystal X-ray diffraction by J. D. Bernal in 1924, while subsequent research tweaked the unit cell parameters. The theory of graphene was first explored by P. R. Wallace in 1947 as a starting point for understanding the electronic properties of 3D graphite. The emergent massless Dirac equation was separately pointed out in 1984 by Gordon Walter Semenoff, and by David P. Vincenzo and Eugene J. Mele. Semenoff emphasized the occurrence in a magnetic field of an electronic Landau level precisely at the Dirac point. This level is responsible for the anomalous integer Quantum Hall effect.
== History == APP was founded in 2007 and incorporated in February 2008 by laboratory professionals, Edward Dooling and Thanasis Papaioanu, along with hospital executive, Martin Rash. Edward Dooling was formerly a senior executive with AmeriPath (now part of Quest Diagnostics) and DIANON Systems, Inc., (now part of LabCorp). Thanasis Papaioanu was formerly an investment banker with SunTrust Equitable (now SunTrust Robinson Humphrey) and FTN Financial (part of First Tennessee National Corporation), where he helped launch New York-based laboratory CBLPath, Inc. (now part of Sonic Healthcare). Martin Rash is founder and Chairman/CEO of RegionalCare Hospital Partners; he was formerly founder and Chairman/CEO of publicly traded Province Healthcare Company that was acquired by Lifepoint Hospitals, Inc. (Nasdaq: LPNT) in 2005. In April 2008, APP secured a $75 million equity commitment from New Enterprise Associates (NEA), a large private equity investment firm based in Menlo Park, California and Baltimore, Maryland. On December 31, 2008, APP completed the acquisition of UniPath, LLC in Denver, Colorado. APP operates the technical operation while UniPath, P.C., the affiliated 25+ pathologist medical practice, stays independent and continues to be owned and managed by the pathologists. On March 12, 2009, the firm completed the acquisition of Eastern Carolina Pathology, Inc. in Wilson, North Carolina.
Sources: en.wikipedia.org
Thermal ionization (also known as surface ionization, or contact ionization) involves spraying vaporized, neutral atoms onto a hot surface, from which the atoms re-evaporate in ionic form. To generate positive ions, the atomic species should have a low ionization energy, and the surface should have a high work function. This technique is most suitable for alkali atoms (Li, Na, K, Rb, Cs) which have low ionization energies and are easily evaporated. To generate negative ions, the atomic species should have a high electron affinity, and the surface should have a low work function. This second approach is most suited for halogen atoms Cl, Br, I, At.
== Mechanism of action == As a sulfonamide antibiotic, sulfanilamide functions by competitively inhibiting (that is, by acting as a substrate analogue of) enzymatic reactions involving para-aminobenzoic acid (PABA). Specifically, it competitively inhibits the enzyme dihydropteroate synthase. PABA is needed in enzymatic reactions that produce folic acid, which acts as a coenzyme in the synthesis of purines and pyrimidines. Mammals do not synthesize their own folic acid so are unaffected by PABA inhibitors, which selectively kill bacteria. However, this effect can be reversed by adding the end products of one-carbon transfer reactions, such as thymidine, purines, methionine, and serine. PABA can also reverse the effects of sulfonamides.
=== Controversy === On June 21, 2014, actor William Shatner raised an issue with several Engadget editorial staff and their verification status on Twitter. Besides the site's social media editor, John Colucci, Shatner also targeted several junior members of the staff for being "nobodies", unlike some of his actor colleagues who did not bear such distinction. Shatner claimed Colucci and the team were bullying him when giving a text interview to Mashable. Over a month later, Shatner continued to discuss the issue on his Tumblr page, to which Engadget replied by defending its team and discussing the controversy surrounding the social media verification. Twitter's practice and process for verifying accounts came under scrutiny again in 2017 after the company verified the account of white supremacist and far-right political activist, Jason Kessler. Many who criticized Twitter's decision to verify Kessler's account saw this as a political act on the company's behalf. In response, Twitter put its verification process on hold. The company tweeted, "Verification was meant to authenticate identity & voice but it is interpreted as an endorsement or an indicator of importance. We recognize that we have created this confusion and need to resolve it. We have paused all general verifications while we work and will report back soon." As of November 2017, Twitter continued to deny verification of Julian Assange's account following his requests.
^ 1 On early U.S. and Canadian pressings, "Down in a Hole" appeared as track 12 placed between "Angry Chair" and "Would?". Current U.S. and Canadian editions of the CD and the Vinyl have "Down in a Hole" as the fourth track, located between "Rain When I Die" and "Sickman", which was the track listing that the band originally intended before the record company changed the order. ^ 2 Track 9 or 10, "Iron Gland", appears without a title on the album. The title appeared on the compilations Nothing Safe and Music Bank. The iTunes Store lists it incorrectly as "Iron Man". Before the name "Iron Gland" was revealed, it was labeled in some online databases as "Intro (Dream Sequence)". On editions in which "Down in a Hole" is track 4, "Iron Gland" is track 10. The track is unlisted on some versions of the album, and some editions remove the track completely or merge it with "Hate to Feel". On the back cover of the edition in which "Iron Gland" is track 9, "Hate to Feel", "Angry Chair", "Down in a Hole" and "Would?" are listed from 9–12. However, when the CD is played, the songs are on tracks 10–13.
== Recognition == In November 2013, Schrödinger, in collaboration with Cycle Computing and the University of Southern California, set a record for the world's largest and fastest cloud computing run by using 156,000 cores on Amazon Web Services to screen over 205,000 molecules for materials science research. That work was a follow-up to a 2012 collaboration which saw Cycle Computing creating a 50,000 core virtual supercomputer using Amazon and Schrödinger's infrastructure; at that time, it was used to analyze 2.1 million compounds in 3 hours.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.